Catalog No.
DVV00506
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2 (2019-nCoV)
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
CC68.109
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603
Self-assembled epitope-based nanoparticles targeting the SARS-CoV-2 spike protein enhanced the immune response and induced potential broad neutralizing activity., PMID:40270771
Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses., PMID:40226608
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques., PMID:39847599
Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo., PMID:39621673
Discovery and characterization of a pan-betacoronavirus S2-binding antibody., PMID:39326419
Structure and inhibition of SARS-CoV-2 spike refolding in membranes., PMID:39146425
Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge., PMID:38378768
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection., PMID:38270455
Deep immunoglobulin repertoire sequencing depicts a comprehensive atlas of spike-specific antibody lineages shared among COVID-19 convalescents., PMID:38044868
Repurposing Navitoclax to block SARS-CoV-2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein., PMID:37804480
An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen., PMID:37534910
Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines., PMID:37164987
The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2., PMID:36972173
A novel mAb broadly neutralizes SARS-CoV-2 VOCs in vitro and in vivo, including the Omicron variants., PMID:36912367
Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix., PMID:36414178
Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein., PMID:36333470
Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants., PMID:36156540
Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2., PMID:35773398
Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit., PMID:35411021
The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes., PMID:35236990
Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil., PMID:35196783
A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection., PMID:35133175
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination., PMID:34812143
Stabilized coronavirus spike stem elicits a broadly protective antibody., PMID:34710354
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions., PMID:34056628
The Potential of Developing Pan-Coronaviral Antibodies to Spike Peptides in Convalescent COVID-19 Patients., PMID:33677719
For research use only. Not for human or drug use.
